|
EP3515916B1
(en)
|
2016-09-22 |
2023-06-07 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
TW202500565A
(zh)
|
2016-10-24 |
2025-01-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
CA3051054A1
(en)
|
2017-01-23 |
2018-07-26 |
Revolution Medicines, Inc. |
Pyridine compounds as allosteric shp2 inhibitors
|
|
CN110446709B
(zh)
|
2017-01-23 |
2023-09-12 |
锐新医药公司 |
作为变构shp2抑制剂的二环化合物
|
|
US11591336B2
(en)
|
2017-05-26 |
2023-02-28 |
D. E. Shaw Research, Llc |
Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
|
|
TWI852912B
(zh)
|
2017-09-07 |
2024-08-21 |
美商銳新醫藥公司 |
Shp2抑制劑組合物以及治療癌症的方法
|
|
EP3687997A1
(en)
|
2017-09-29 |
2020-08-05 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
BR112020007058A2
(pt)
|
2017-10-12 |
2020-10-06 |
Revolution Medicines, Inc. |
compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
|
|
BR112020009757A2
(pt)
*
|
2017-12-15 |
2020-11-03 |
Revolution Medicines, Inc. |
compostos policíclicos como inibidores alostéricos de shp2
|
|
US12138263B2
(en)
|
2018-03-21 |
2024-11-12 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
|
|
CN117263942A
(zh)
|
2018-03-21 |
2023-12-22 |
传达治疗有限公司 |
Shp2磷酸酶抑制剂及其使用方法
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
CN117143079A
(zh)
|
2018-11-06 |
2023-12-01 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物及其应用
|
|
WO2020108590A1
(zh)
*
|
2018-11-30 |
2020-06-04 |
上海拓界生物医药科技有限公司 |
嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
|
|
US20220380385A1
(en)
*
|
2019-06-28 |
2022-12-01 |
Tuojie Biotech(Shanghai) Co., Ltd. |
Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
|
|
CN111704611B
(zh)
*
|
2019-07-25 |
2022-01-14 |
上海凌达生物医药有限公司 |
一类芳基螺环类shp2抑制剂化合物、制备方法和用途
|
|
CN112300160A
(zh)
*
|
2019-08-01 |
2021-02-02 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物、其制备及应用
|
|
EP3772513A1
(en)
|
2019-08-09 |
2021-02-10 |
C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening |
Shp2 inhibitors
|
|
EP4034539A1
(en)
|
2019-09-24 |
2022-08-03 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of making and using the same
|
|
WO2021088945A1
(zh)
*
|
2019-11-08 |
2021-05-14 |
南京圣和药业股份有限公司 |
作为shp2抑制剂的化合物及其应用
|
|
CN113754683A
(zh)
*
|
2020-06-05 |
2021-12-07 |
上海奕拓医药科技有限责任公司 |
同位素取代的螺芳环化合物及其应用
|
|
US12686691B2
(en)
|
2020-06-18 |
2026-07-21 |
Etern Biopharma (Shanghai) Co., Ltd. |
Crystalline form of SHP2 inhibitor, and composition thereof, preparation method therefor, and use thereof
|
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
|
EP4208261A1
(en)
|
2020-09-03 |
2023-07-12 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
CN114380845B
(zh)
*
|
2020-10-19 |
2025-06-20 |
四川科伦博泰生物医药股份有限公司 |
一种并杂环类化合物，包含其的药物组合物，其制备方法及其用途
|
|
CN114478585A
(zh)
*
|
2020-10-26 |
2022-05-13 |
上海青煜医药科技有限公司 |
含氮稠杂环类化合物及其制备方法和应用
|
|
WO2022089389A1
(zh)
*
|
2020-10-30 |
2022-05-05 |
赣江新区博瑞创新医药有限公司 |
杂环化合物及其制备方法、药物组合物和应用
|
|
TW202241902A
(zh)
*
|
2020-12-25 |
2022-11-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
一種嘧啶并五元氮雜環類衍生物的晶型及其製備方法
|
|
US20240140931A1
(en)
*
|
2021-02-05 |
2024-05-02 |
Hutchmed Limited |
Tricyclic compounds and uses thereof
|
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN115304612A
(zh)
*
|
2021-05-08 |
2022-11-08 |
南京圣和药业股份有限公司 |
杂环类shp2抑制剂的晶型
|
|
CN115300513A
(zh)
*
|
2021-05-08 |
2022-11-08 |
南京圣和药业股份有限公司 |
一种包含杂环类shp2抑制剂的组合物及其用途
|
|
CN115304613A
(zh)
*
|
2021-05-08 |
2022-11-08 |
南京圣和药业股份有限公司 |
杂环类shp2抑制剂的制备方法
|
|
TW202313041A
(zh)
|
2021-06-09 |
2023-04-01 |
瑞士商諾華公司 |
包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
TW202328133A
(zh)
*
|
2021-08-27 |
2023-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Shp2抑制劑治療含有ras通路基因突變的腫瘤的用途
|
|
US20240374571A1
(en)
|
2021-09-01 |
2024-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
EP4227307A1
(en)
*
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
CN117003772B
(zh)
*
|
2022-04-28 |
2026-02-27 |
博瑞生物医药（苏州）股份有限公司 |
杂环化合物的可药用盐及其晶型、制备方法和用途
|
|
AU2023269154B2
(en)
*
|
2022-05-12 |
2026-05-14 |
Genentech, Inc. |
Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
|
|
CN114920759B
(zh)
*
|
2022-05-18 |
2024-09-10 |
江南大学 |
杂环-三氮唑并噻二唑杂环串联化合物、合成方法、药物组合物及用途
|
|
CN117209500B
(zh)
*
|
2022-06-01 |
2026-04-10 |
上海凌达生物医药有限公司 |
Shp2抑制剂、其晶型及其制备方法与用途
|
|
WO2023230968A1
(zh)
*
|
2022-06-01 |
2023-12-07 |
上海凌达生物医药有限公司 |
Shp2抑制剂、其晶型及其制备方法与用途
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024125603A1
(zh)
*
|
2022-12-15 |
2024-06-20 |
江苏威凯尔医药科技有限公司 |
Shp2抑制剂及其应用
|
|
CN116354960A
(zh)
*
|
2023-03-19 |
2023-06-30 |
药雅科技(上海)有限公司 |
Shp2磷酸酶抑制剂
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|